Ridocox 0.5% Premix

Indications

• Gastrointestinal disturbances
• Toxin adsorption in cases of poisoning
• Diarrhea
• Gastroenteritis

Dosage

Children: Refer to the specific product guidelines or consult clinical resources for dosing recommendations.

Adults: Refer to the specific product guidelines or consult clinical resources for dosing recommendations.

Mechanism of action

Bentonite works by adsorbing toxins and pathogens in the gastrointestinal tract. The high surface area and negative charge of bentonite particles attract positively charged ions, allowing it to bind to various substances, including bacteria and toxins, thereby facilitating their removal from the body.

Pharmacodynamics

Bentonite's pharmacodynamic properties are largely attributed to its adsorptive capacity. It can effectively bind to various drugs and toxins, reducing their bioavailability. This property makes it useful in treating cases of poisoning or overdose, as it can prevent the absorption of harmful substances in the intestines.

Pharmacokinetics

Bentonite is not absorbed systemically. After oral administration, it remains in the gastrointestinal tract where it exerts its effects. The clay is eventually excreted in the feces. The onset of action can vary depending on the formulation and the presence of other substances in the gastrointestinal tract.

Adverse effects

• Constipation
• Abdominal discomfort
• Nausea

Interactions

• May reduce the absorption of other medications when taken concurrently

Precautions

• Use with caution in patients with gastrointestinal obstructions
• Ensure adequate hydration to prevent constipation

Pregnancy

Bentonite is generally considered safe during pregnancy; however, clinical data is limited.

Breast-feeding

Bentonite is likely safe during breastfeeding, but consult a healthcare professional for personalized advice.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Suspension

Indications

• Food preservative
• Treatment of urea cycle disorders
• Metabolic disorders involving benzoyl-CoA

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines based on condition.

Adults: Refer to the BNF for specific dosing guidelines based on condition.

Mechanism of action

Benzoate acts mainly by inhibiting the growth of bacteria and fungi through its ability to lower the pH, creating an environment that is less favorable for microbial growth. It is also involved in metabolic pathways where it helps in the conjugation of toxic substances, facilitating their excretion from the body.

Pharmacodynamics

Benzoate is known for its antimicrobial properties, which are particularly effective against a wide range of fungi and bacteria. Its efficacy as a preservative is due to its ability to penetrate microbial cell membranes and disrupt their metabolic processes. Additionally, it has been observed to modulate various metabolic pathways, particularly those associated with aromatic compound degradation.

Pharmacokinetics

After ingestion, benzoate is rapidly absorbed in the gastrointestinal tract. It is metabolized primarily in the liver, where it undergoes conjugation with glycine to form hippurate, which is then excreted in the urine. The half-life of benzoate varies depending on individual metabolic rates but is generally short due to its efficient conversion and excretion.

Pregnancy

There is limited data on the use of benzoate in pregnancy. Consultation with healthcare professionals is advised before use.

Breast-feeding

Limited data is available on the excretion of benzoate in breast milk. Caution is recommended when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Coccidiosis in poultry
• Coccidiosis in livestock
• Prevention of coccidiosis in young animals

Dosage

Children: Refer to the BNF for Children for appropriate dosing based on age, weight, and specific conditions.

Adults: Refer to the BNF for specific dosing recommendations based on the type of animal and severity of the condition.

Mechanism of action

Diclazuril functions by inhibiting mitochondrial respiration in the apicomplexan parasites. It disrupts the electron transport chain, leading to decreased ATP production, which is essential for the parasite's survival and reproduction.

Pharmacodynamics

The pharmacodynamics of diclazuril involve its selective action on the coccidian parasites, leading to effective inhibition of their growth and reproduction. The drug primarily affects the intracellular stages of the parasites, with a significant impact on the sporulated oocysts and meronts. This selective toxicity limits its effects on host cells, making it a preferred agent in veterinary medicine.

Pharmacokinetics

Diclazuril is absorbed well when administered orally, with peak plasma concentrations occurring within a few hours post-administration. It is metabolized in the liver and has a relatively long half-life, allowing for once-daily dosing. The drug is primarily excreted in feces, with minimal renal excretion. Its pharmacokinetic profile supports effective treatment with sustained therapeutic levels.

Adverse effects

• Gastrointestinal disturbances
• Neurological effects
• Hypersensitivity reactions

Precautions

• Use with caution in animals with known hypersensitivity to the drug.
• Monitor for signs of toxicity, especially in the presence of hepatic impairment.

Pregnancy

There is limited information on the use of diclazuril in pregnant individuals. Consult relevant guidelines for specific recommendations.

Breast-feeding

Limited data available; consult relevant guidelines for specific recommendations regarding use during breastfeeding.

Storage

Store in a cool, dry place, protected from light.

Formulations

• Oral formulation
• Injectable formulation